Vaccine compositions including chitosan for intranasal...

Details Vaccine compositions including chitosan for intranasal... Vaccine compositions including chitosan for intranasal...

2008-01-29

2008-01-29

Parkin, J. S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S206100, C424S240100, C514S055000

Reexamination Certificate

active

07323183

ABSTRACT:
There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.

REFERENCES:
patent: 4950740 (1990-08-01), Greenfield et al.
patent: 5554388 (1996-09-01), Illum et al.
patent: 5629011 (1997-05-01), Illum et al.
patent: 5912000 (1999-06-01), Podolski et al.
patent: 6048536 (2000-04-01), Chatfield
patent: 0 460 020 (1991-12-01), None
patent: 0 183 556 (1996-06-01), None
patent: WO 90 09780 (1990-09-01), None
patent: WO 96 09805 (1996-04-01), None
patent: WO 96 10421 (1996-04-01), None
patent: WO 97 16208 (1997-05-01), None
Bussiere, J., et al. 1995. Preclinical safety assessment considerations in vaccine development. in Vaccine Design: The subunit an adjuvant approach, Powell, M. F., et al., eds., Plenum Press, New York, pp. 67-71.
Kong, D., et al. 1995. Whole-virus vaccine development by continuous culture on a complementing host. Biotechnol. 13(6):583-586 (abstract provided).
Powers, D. C. 1994. Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women. Clin. Diag. Lab. Immunol. 1(1):16-20 (abstract provided).
Race, E., et al. 1995. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine 13(1):54-60 (abstract provided).
Aspden, et al. “Chitosan as a nasal delivery system: Evaluation of the effect of chitosan on mucociliary clearance rate in the frong palate model,”Internat. J. Pharmaceut., 122:69-78 (1995).
Cahill, et al. “Mice are protected againstBordetella pertussisinfection by intra-nasal immunization with filamentous haemagglutinin,” FEMS Microbiology Letters, 107:211-16 (1993).
de Haan, et al. “Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes,”Vaccine13(2):155-62 (1995).
Hibberd, et al. “Immunization Strategies for the Immunocompromised Host: The Need for Immunoadjuvants,”Ann. Intern. Med., 110:995-96 (1989).
Illum, et al. “Chitosan as a novel nasal delivery system for peptide drugs,” Pharmaceut. Res. 11(8):1186-1189 (1994).
Nishimura, et al. “Adjuvant activity of chitin derivatives in mice and guinea-pigs,”Vaccine3(5):379-84 (1985).
Oka, et al. “Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally,”Vaccine12(14):1255-58 (1994).
Polk, et al. “Oral delivery in aquaculture: controlled release of proteins from chitosan-alginate microcapsules,” Aquacult. Engineer. 13:311-323 (1994).

Affiliated with

Also associated with

Rating

Vaccine compositions including chitosan for intranasal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine compositions including chitosan for intranasal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine compositions including chitosan for intranasal... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2783335